Nalaganje...

Reduced erlotinib sensitivity of EGFR mutant non-small cell lung cancer following cisplatin exposure: A cell culture model of second-line erlotinib treatment

Epidermal growth factor receptor (EGFR) kinase inhibitors induce dramatic clinical responses in a subset of non-small cell lung cancer (NSCLC) patients with advanced disease, and such responses are correlated with the presence of somatic activating mutations within the EGFR kinase domain. Consequent...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Chin, Tan Min, Quinlan, Margaret P., Singh, Anurag, Sequist, Lecia V., Lynch, Thomas J., Haber, Daniel A., Sharma, Sreenath V., Settleman, Jeffrey
Format: Artigo
Jezik:Inglês
Izdano: 2008
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2710881/
https://ncbi.nlm.nih.gov/pubmed/18980981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0093
Oznake: Označite
Brez oznak, prvi označite!